Feature | July 26, 2012

CONFIRM Study Shows AF Sustained by Localized Rotors, Focuses Where to Ablate

Study shows atrial fibrillation source can be imaged and eliminated with short, targeted ablation therapy

July 26, 2012 — A new study shows promising data for a new method to image the source of atrial fibrillation (AF) and target its ablation to greatly reduce procedure time and substantially improve patient outcomes. The results of the CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) study were published online this week by the Journal of the American College of Cardiology.

The study found AF is typically caused by very few localized sources that cause disorganization in the remaining atria. Focal impulse and rotor modulation (FIRM) ablation to eliminate these sources was able to abruptly terminate or consistently slow persistent and paroxysmal AF in the vast majority of cases, and substantially improve long-term AF elimination over conventional ablation alone in this prospective case-cohort study. FIRM mapping may open the possibility for several patient-tailored therapies for AF in addition to ablation for this highly prevalent disease with major public health and societal impact. The authors concluded these results offer a novel mechanistic framework and treatment paradigm for AF.

Researchers said catheter ablation for AF is a promising therapy, but success is limited in part by uncertainty in the mechanisms that sustain AF. They developed a computational approach to map whether AF is sustained by several meandering waves or localized sources, then prospectively tested whether targeting patient-specific mechanisms revealed by mapping would improve AF ablation outcome.

The study recruited 92 subjects during 107 consecutive ablation procedures for paroxysmal or persistent (72 percent) AF. Computational AF maps were generated intraprocedurally in the FIRM-guided group, and post-procedure in the FIRM-blinded group using a novel system (RhythmView, Topera Medical, Lexington, Mass). The FIRM maps of AF revealed electrical rotors defined as sequential clockwise or counterclockwise activation contours (isochrones) around a center of rotation emanating outward to control local AF activation, or focal impulses defined by centrifugal activation contours (isochrones) from an origin. Rotors and focal impulses showed limited spatial precession and were considered AF sources only if consistent in multiple recordings over 10 minutes (equating to thousands of cycles) to eliminate transient AF patterns of unclear functional significance.

In FIRM-guided subjects, ablation commenced with FIRM to eliminate sources. Radiofrequency energy was delivered using a 3.5 mm tip irrigated catheter (Thermocool, Biosense-Webster). The catheter was maneuvered to the basket electrode overlying each source, using fluoroscopy (or digital atrial mapping), and radiofrequency energy was applied for 15 seconds to 30 seconds. The catheter was moved within the area indicated by FIRM maps to represent the center of rotation or focal impulse origin until AF terminated or ablation time at that source reached less than or equal to 10 min, whichever came first (typically less than 5 minutes per source).

For more information: http://content.onlinejacc.org/article.aspx?articleid=1221482

Related Content

Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems| October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Spectranetics Initiates Class I Recall for Bridge Occlusion Balloon Catheter
News | EP Lab| September 27, 2017
Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in...
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
News | Vena Cava Filters| September 26, 2017
September 26, 2017 — The one-year results of the SENTRY...
Overlay Init